2'-Fucosyllactose attenuates estrogen-deficiency-associated bone loss and intestinal dysfunction in ovariectomized rats.
BACKGROUND Postmenopausal osteoporosis (PMO), driven primarily by estrogen deficiency, is the most prevalent form of osteoporosis and a major global health burden. Estrogen deficiency disrupts gut microbial homeostasis, compromises intestinal barrier integrity and promotes inflammatory bone loss partly through dysregul...